PL3294323T3 - Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego - Google Patents
Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowegoInfo
- Publication number
- PL3294323T3 PL3294323T3 PL16797013T PL16797013T PL3294323T3 PL 3294323 T3 PL3294323 T3 PL 3294323T3 PL 16797013 T PL16797013 T PL 16797013T PL 16797013 T PL16797013 T PL 16797013T PL 3294323 T3 PL3294323 T3 PL 3294323T3
- Authority
- PL
- Poland
- Prior art keywords
- nervous system
- central nervous
- therapeutic delivery
- adenovirus virus
- adenovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162174P | 2015-05-15 | 2015-05-15 | |
| US201562252055P | 2015-11-06 | 2015-11-06 | |
| US201662301980P | 2016-03-01 | 2016-03-01 | |
| US201662331156P | 2016-05-03 | 2016-05-03 | |
| EP16797013.6A EP3294323B1 (en) | 2015-05-15 | 2016-05-13 | Adeno-associated virus for therapeutic delivery to central nervous system |
| PCT/US2016/032392 WO2016187017A1 (en) | 2015-05-15 | 2016-05-13 | Adeno-associated for therapeutic delivery to central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3294323T3 true PL3294323T3 (pl) | 2022-06-20 |
Family
ID=57320277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16797013T PL3294323T3 (pl) | 2015-05-15 | 2016-05-13 | Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20180289839A1 (pl) |
| EP (2) | EP3294323B1 (pl) |
| JP (4) | JP2018515615A (pl) |
| KR (3) | KR20220082100A (pl) |
| CN (1) | CN108367055A (pl) |
| AU (2) | AU2016263119B2 (pl) |
| BR (1) | BR112017024519A2 (pl) |
| CA (1) | CA2986252A1 (pl) |
| CY (1) | CY1125229T1 (pl) |
| DK (1) | DK3294323T3 (pl) |
| ES (1) | ES2901766T3 (pl) |
| HK (1) | HK1256341A1 (pl) |
| HR (1) | HRP20220050T1 (pl) |
| HU (1) | HUE057795T2 (pl) |
| LT (1) | LT3294323T (pl) |
| MX (2) | MX2017014443A (pl) |
| PL (1) | PL3294323T3 (pl) |
| PT (1) | PT3294323T (pl) |
| RS (1) | RS63927B1 (pl) |
| RU (1) | RU2751952C2 (pl) |
| SI (1) | SI3294323T1 (pl) |
| SM (1) | SMT202200022T1 (pl) |
| WO (1) | WO2016187017A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971039B1 (en) | 2013-03-14 | 2020-01-01 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| EP3747998B1 (en) | 2013-03-15 | 2024-07-24 | The Trustees of the University of Pennsylvania | Compositions for treating mpsi |
| RU2692251C2 (ru) * | 2013-05-15 | 2019-06-24 | Риджентс Оф Зэ Юниверсити Оф Миннесота | Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2016187017A1 (en) | 2015-05-15 | 2016-11-24 | Mcivor R Scott | Adeno-associated for therapeutic delivery to central nervous system |
| US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
| WO2017181113A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
| KR20190086503A (ko) * | 2016-11-15 | 2019-07-22 | 리젠츠 오브 더 유니버시티 오브 미네소타 | Mpsi 및 mpsii에서의 신경계 기능 및 다른 신경계 장애를 개선하는 방법 |
| WO2018191666A1 (en) | 2017-04-14 | 2018-10-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells |
| CN110709090A (zh) * | 2017-04-27 | 2020-01-17 | 益缪索夫特公司 | 用于在体内递送治疗剂的b细胞及其剂量 |
| JP2020526514A (ja) * | 2017-07-06 | 2020-08-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症i型を治療するための遺伝子治療 |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| US11802294B2 (en) | 2017-10-03 | 2023-10-31 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CA3083761A1 (en) | 2017-11-30 | 2019-06-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for mucopolysaccharidosis iiib |
| WO2019199841A1 (en) * | 2018-04-09 | 2019-10-17 | Cure Ahc, Inc. | Aav-mediated delivery of atp1a3 genes to central nervous system |
| IL280198B1 (en) * | 2018-07-18 | 2025-09-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| MX2021010266A (es) * | 2019-02-26 | 2021-09-23 | Univ Pennsylvania | Composiciones utiles en el tratamiento de la enfermedad de krabbe. |
| CN113811359A (zh) * | 2019-03-22 | 2021-12-17 | 拉什大学医学中心 | 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合 |
| WO2020210713A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| WO2020227166A1 (en) * | 2019-05-03 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| MX2021015076A (es) * | 2019-06-10 | 2022-06-02 | Homology Medicines Inc | Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas. |
| CA3155154A1 (en) * | 2019-10-23 | 2021-04-29 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4072595A1 (en) | 2019-12-10 | 2022-10-19 | Takeda Pharmaceutical Company Limited | Adeno associated virus vectors for the treatment of hunter disease |
| JP2023537903A (ja) * | 2020-08-10 | 2023-09-06 | プリベイル セラピューティクス,インコーポレーテッド | リソソーム障害に対する遺伝子療法 |
| CN117642173A (zh) * | 2020-12-07 | 2024-03-01 | 华东理工大学 | 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒 |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| CA3209611A1 (en) | 2021-02-10 | 2022-08-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| US20240366789A1 (en) * | 2021-04-01 | 2024-11-07 | The University Of North Carolina At Chapel Hill | Aav-ids vectors for treatment of mucopolysaccharidosis ii |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| ATE272123T1 (de) | 1993-11-09 | 2004-08-15 | Ohio Med College | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5656785A (en) | 1995-08-07 | 1997-08-12 | The Charles Stark Draper Laboratory, Inc. | Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor |
| AU5445998A (en) | 1996-11-19 | 1998-06-10 | Surgx Corporation | A transient voltage protection device and method of making same |
| CA2270285A1 (en) | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
| EP1915986A1 (en) | 2006-10-23 | 2008-04-30 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Lipid growth factor formulations |
| ES2634118T3 (es) * | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
| EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| HRP20191924T1 (hr) * | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku iduronat-2-sulfataze u cns |
| WO2012135857A1 (en) * | 2011-03-31 | 2012-10-04 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| US8609088B2 (en) * | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
| US20130039888A1 (en) * | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
| CA2852955C (en) * | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| RU2692251C2 (ru) * | 2013-05-15 | 2019-06-24 | Риджентс Оф Зэ Юниверсити Оф Миннесота | Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему |
| MX373332B (es) * | 2013-07-26 | 2020-05-21 | Univ Iowa Res Found | UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES. |
| WO2016187017A1 (en) * | 2015-05-15 | 2016-11-24 | Mcivor R Scott | Adeno-associated for therapeutic delivery to central nervous system |
| KR20190086503A (ko) * | 2016-11-15 | 2019-07-22 | 리젠츠 오브 더 유니버시티 오브 미네소타 | Mpsi 및 mpsii에서의 신경계 기능 및 다른 신경계 장애를 개선하는 방법 |
| CA3209611A1 (en) * | 2021-02-10 | 2022-08-18 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
-
2016
- 2016-05-13 WO PCT/US2016/032392 patent/WO2016187017A1/en not_active Ceased
- 2016-05-13 LT LTEPPCT/US2016/032392T patent/LT3294323T/lt unknown
- 2016-05-13 PL PL16797013T patent/PL3294323T3/pl unknown
- 2016-05-13 HK HK18115428.0A patent/HK1256341A1/zh unknown
- 2016-05-13 KR KR1020227018782A patent/KR20220082100A/ko not_active Ceased
- 2016-05-13 MX MX2017014443A patent/MX2017014443A/es unknown
- 2016-05-13 HU HUE16797013A patent/HUE057795T2/hu unknown
- 2016-05-13 CN CN201680037625.2A patent/CN108367055A/zh active Pending
- 2016-05-13 RU RU2017143640A patent/RU2751952C2/ru active
- 2016-05-13 KR KR1020177036062A patent/KR102406615B1/ko active Active
- 2016-05-13 EP EP16797013.6A patent/EP3294323B1/en active Active
- 2016-05-13 SI SI201631430T patent/SI3294323T1/sl unknown
- 2016-05-13 CA CA2986252A patent/CA2986252A1/en active Pending
- 2016-05-13 PT PT167970136T patent/PT3294323T/pt unknown
- 2016-05-13 ES ES16797013T patent/ES2901766T3/es active Active
- 2016-05-13 JP JP2018511353A patent/JP2018515615A/ja active Pending
- 2016-05-13 EP EP21201643.0A patent/EP4000631A1/en not_active Withdrawn
- 2016-05-13 AU AU2016263119A patent/AU2016263119B2/en active Active
- 2016-05-13 HR HRP20220050TT patent/HRP20220050T1/hr unknown
- 2016-05-13 RS RS20211570A patent/RS63927B1/sr unknown
- 2016-05-13 KR KR1020257032548A patent/KR20250150167A/ko active Pending
- 2016-05-13 SM SM20220022T patent/SMT202200022T1/it unknown
- 2016-05-13 DK DK16797013.6T patent/DK3294323T3/da active
- 2016-05-13 US US15/574,432 patent/US20180289839A1/en not_active Abandoned
- 2016-05-13 BR BR112017024519-1A patent/BR112017024519A2/en not_active Application Discontinuation
-
2017
- 2017-11-10 MX MX2022012524A patent/MX2022012524A/es unknown
- 2017-11-15 US US15/813,908 patent/US20180071373A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/344,308 patent/US20210369871A1/en not_active Abandoned
- 2021-07-05 JP JP2021111318A patent/JP2021167332A/ja not_active Withdrawn
- 2021-11-12 AU AU2021266344A patent/AU2021266344B2/en active Active
-
2022
- 2022-01-12 US US17/574,118 patent/US20220211875A1/en not_active Abandoned
- 2022-01-13 CY CY20221100032T patent/CY1125229T1/el unknown
- 2022-07-19 JP JP2022114547A patent/JP2022137261A/ja active Pending
-
2023
- 2023-01-05 US US18/150,740 patent/US20230226225A1/en not_active Abandoned
-
2024
- 2024-07-17 JP JP2024113975A patent/JP2024147704A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3294323T3 (pl) | Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego | |
| DK3328880T3 (da) | Terapeutiske midler | |
| DK3265421T3 (da) | Doseringssystem | |
| IL253719A0 (en) | Pharmaceutical compositions for combination therapy | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| DK3139986T3 (da) | System til administration af terapeutisk gas | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| MA40764A (fr) | Agent thérapeutique induisant une cytotoxicité | |
| DK3262066T4 (da) | Genterapi | |
| GB201500463D0 (en) | Therapeutic molecules | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| GB201500461D0 (en) | Therapeutic molecules | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| EP3389589C0 (en) | MEDICAL DELIVERY DEVICE | |
| DK3310800T3 (da) | Leveringssystem til styret lægemiddelfrigivelse | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| EP3246047C0 (en) | COMBINATION MEDICATION | |
| DK3288955T3 (da) | Bortezomib-baseret afgivelsessystem | |
| EP3244868C0 (en) | DRUG DELIVERY DEVICES | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3310379T3 (da) | Vegfr-2-targeterende dna-vaccine til kombinationsterapi | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| EP4233950C0 (en) | NASAL ADMINISTRATION |